IL103252A - CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Google Patents

CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Info

Publication number
IL103252A
IL103252A IL103252A IL10325292A IL103252A IL 103252 A IL103252 A IL 103252A IL 103252 A IL103252 A IL 103252A IL 10325292 A IL10325292 A IL 10325292A IL 103252 A IL103252 A IL 103252A
Authority
IL
Israel
Prior art keywords
alkyl
substituted
nr13r14
nr14c
nhr13
Prior art date
Application number
IL103252A
Other languages
English (en)
Other versions
IL103252A0 (en
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of IL103252A0 publication Critical patent/IL103252A0/xx
Publication of IL103252A publication Critical patent/IL103252A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL103252A 1991-09-30 1992-09-23 CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM IL103252A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76784891A 1991-09-30 1991-09-30
US94928592A 1992-09-09 1992-09-09

Publications (2)

Publication Number Publication Date
IL103252A0 IL103252A0 (en) 1993-02-21
IL103252A true IL103252A (en) 1997-03-18

Family

ID=27117970

Family Applications (1)

Application Number Title Priority Date Filing Date
IL103252A IL103252A (en) 1991-09-30 1992-09-23 CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Country Status (15)

Country Link
EP (1) EP0625164B1 (xx)
JP (1) JPH07502023A (xx)
AT (1) ATE178614T1 (xx)
AU (1) AU672178B2 (xx)
CA (1) CA2120362A1 (xx)
DE (1) DE69228881T2 (xx)
DK (1) DK0625164T3 (xx)
ES (1) ES2131533T3 (xx)
FI (1) FI941457A (xx)
GR (1) GR3029931T3 (xx)
HU (1) HUT68094A (xx)
IL (1) IL103252A (xx)
MX (1) MX9205574A (xx)
NZ (1) NZ244528A (xx)
WO (1) WO1993007170A1 (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817749A (en) * 1993-03-29 1998-10-06 Dupont Pharmaceuticals Company Processes and intermediate compounds for the preparation of platelet glycoprotein IIb/IIIa inhibitors

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635477A (en) * 1991-09-30 1997-06-03 The Dupont Merck Pharmaceutical Company Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA
US5968476A (en) * 1992-05-21 1999-10-19 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
JPH08503217A (ja) * 1992-11-18 1996-04-09 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー 血小板糖タンパク質▲ＩＩ▼ｂ／▲ＩＩＩ▼ａの阻害剤として有用な複素環式環により結合された環状化合物
NZ263456A (en) * 1993-03-29 1996-11-26 Du Pont Merck Pharma Cyclic compounds useful as inhibitors of platelet glycoprotein iib/iiia and medicaments thereof
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
CA2162113A1 (en) * 1993-05-13 1994-11-24 Thomas Peter Maduskuie Jr. Processes and intermediate compounds useful for the preparation of platelet glycoprotein iib/iiia inhibitors
WO1995023811A1 (en) * 1994-03-04 1995-09-08 The Du Pont Merck Pharmaceutical Company Novel carbocyclic compounds which inhibit platelet aggregation by interaction with the gpiib/iiia receptor complex
DE4415310A1 (de) * 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptide
US5879659A (en) * 1996-03-13 1999-03-09 Dupont Pharmaceuticals Company Ternary radiopharmaceutical complexes
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104159595A (zh) 2012-02-15 2014-11-19 爱勒让治疗公司 拟肽大环化合物
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
WO2016049355A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857508A (en) 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
AU3040589A (en) 1988-02-22 1989-09-06 Upjohn Company, The Homoarginine-based peptides as platelet aggregation inhibitors
ZW6189A1 (en) 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
FR2631626B1 (fr) 1988-05-20 1990-08-10 Centre Nat Rech Scient Nouveaux pentapeptides et leurs applications en tant que medicaments, notamment antithrombotiques
JP2945680B2 (ja) 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5084466A (en) 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5120859A (en) 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
US4952562A (en) 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
NZ235564A (en) 1989-10-13 1993-10-26 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical compositions
NZ235563A (en) 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
CA2027936C (en) 1989-10-23 2001-07-24 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817749A (en) * 1993-03-29 1998-10-06 Dupont Pharmaceuticals Company Processes and intermediate compounds for the preparation of platelet glycoprotein IIb/IIIa inhibitors

Also Published As

Publication number Publication date
EP0625164B1 (en) 1999-04-07
GR3029931T3 (en) 1999-07-30
HUT68094A (en) 1995-05-29
DE69228881D1 (de) 1999-05-12
WO1993007170A1 (en) 1993-04-15
ES2131533T3 (es) 1999-08-01
MX9205574A (es) 1993-03-01
JPH07502023A (ja) 1995-03-02
EP0625164A1 (en) 1994-11-23
CA2120362A1 (en) 1993-04-15
HU9400912D0 (en) 1994-06-28
ATE178614T1 (de) 1999-04-15
DK0625164T3 (da) 1999-10-18
DE69228881T2 (de) 1999-10-14
NZ244528A (en) 1995-02-24
AU2756192A (en) 1993-05-03
FI941457A0 (fi) 1994-03-29
FI941457A (fi) 1994-03-29
AU672178B2 (en) 1996-09-26
IL103252A0 (en) 1993-02-21

Similar Documents

Publication Publication Date Title
IL103252A (en) CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NZ330868A (en) 4-phenoxy, phenylthio or phenylamino substituted quinazoline derivatives ane medicaments useful as VEGF inhibitors
MY109737A (en) Treatment and compounds.
HUP0400570A2 (hu) Feniletenil- vagy feniletinil-heteroaril-származékok mint glutamát receptor antagonisták, alkalmazásuk, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MY129540A (en) Quinazoline derivatives, pharmaceutical compositions containing them processes for their preparation and their use in the production of an antiangiogenic and/or vascular permeability reducing effect
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
BR0214989A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças, e, processo para a preparação de um composto
NO20021399L (no) Kazolinderivater og deres anvendelse som farmasöyter
BR0012646A (pt) Composto, análogo de oligonucleotìdeo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um análogo de oligonucleotìdeo
HUP0101281A2 (hu) Glicin transzport inhibitor hatású difenil-piperidin-butánamid-származékok, eljárás előállításukra, alkalmazásuk gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
DE3660286D1 (en) Arylcyclobutylalkyl amines and their use as antidepressive medicines
EP1640367A4 (en) ISOQUINOLINE-1,3,4-TRIONE, SYNTHETIC PROCESS AND USE THEREOF
CO5200847A1 (es) Metodos y composiciones para tratar enfermedades y condiciones del ojo
NO975295L (no) 6-Karbamido-dihydropyran-derivater
ES2184467T3 (es) Derivados de la piperacina para la inhibicion de la replicacion del virus de la inmunodeficiencia humana.
DK0707570T3 (da) Isoquinolinderivater som terapeutiske midler
DE69217613D1 (de) Stickstoff enthaltende bizyklische Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE69229607D1 (de) 1,4-Dihydropyridin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Zusammensetzung
DE69015787T2 (de) Thiophenderivate, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
IL103595A0 (en) 2-heterocyclicethylamine derivatives,their preparation and pharmaceutical compositions containing them
HUP0203383A2 (hu) Aminofenoxiacetamid-származékok és ilyen vegyületeket tartalmazó gyógyászati készítmények
ZA200703275B (en) 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinollnecarbonitriles for the treatment of ischemic Injury
YU34499A (sh) Derivati 5-aroilnaftalena
RU2003130062A (ru) Бициклические производные гуанидина и их терапевтическое использование
AR035613A1 (es) Compuesto derivado de 2-piperidilimidazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento

Legal Events

Date Code Title Description
FF Patent granted
RH Patent void